» Articles » PMID: 34045438

Cyst(e)ine in Nutrition Formulation Promotes Colon Cancer Growth and Chemoresistance by Activating MTORC1 and Scavenging ROS

Overview
Date 2021 May 28
PMID 34045438
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Weight loss and cachexia are common problems in colorectal cancer patients; thus, parenteral and enteral nutrition support play important roles in cancer care. However, the impact of nonessential amino acid components of nutritional intake on cancer progression has not been fully studied. In this study, we discovered that gastrointestinal cancer patients who received cysteine as part of the parenteral nutrition had shorter overall survival (P < 0.001) than those who did not. Cystine indeed robustly promotes colon cancer cell growth in vitro and in immunodeficient mice, predominately by inhibiting SESN2 transcription via the GCN2-ATF4 axis, resulting in mTORC1 activation. mTORC1 inhibitors Rapamycin and Everolimus block cystine-induced cancer cell proliferation. In addition, cystine confers resistance to oxaliplatin and irinotecan chemotherapy by quenching chemotherapy-induced reactive oxygen species via synthesizing glutathione. We demonstrated that dietary deprivation of cystine suppressed colon cancer xenograft growth without weight loss in mice and boosted the antitumor effect of oxaliplatin. These findings indicate that cyst(e)ine, as part of supplemental nutrition, plays an important role in colorectal cancer and manipulation of cyst(e)ine content in nutritional formulations may optimize colorectal cancer patient survival.

Citing Articles

Knockdown of SESN2 Exacerbates Cerebral Ischemia-Reperfusion Injury Through Enhancing Glycolysis via the mTOR/HIF-1α Pathway.

Wang Z, Huang Y, Zhang Y, Zhu H, Amin M, Chen R CNS Neurosci Ther. 2025; 31(3):e70314.

PMID: 40032632 PMC: 11875773. DOI: 10.1111/cns.70314.


Systematic exploration of the molecular characteristics of CD8 T cells to predict the response to immunotherapy and the prognosis of patients with colon adenocarcinoma.

Shen X, Shang L, Han J, Zhang Y, Niu W, Liu H Heliyon. 2024; 10(23):e39260.

PMID: 39669138 PMC: 11636100. DOI: 10.1016/j.heliyon.2024.e39260.


CES1 is associated with cisplatin resistance and poor prognosis of head and neck squamous cell carcinoma.

Jiang C, Liu C, Yao X, Su J, Lu W, Wei Z Oncol Res. 2024; 32(12):1935-1948.

PMID: 39574476 PMC: 11576922. DOI: 10.32604/or.2024.052244.


Oncogenic accumulation of cysteine promotes cancer cell proliferation by regulating the translation of D-type cyclins.

Okano Y, Yamauchi T, Fukuzaki R, Tsuruta A, Yoshida Y, Tsurudome Y J Biol Chem. 2024; 300(11):107890.

PMID: 39413876 PMC: 11650723. DOI: 10.1016/j.jbc.2024.107890.


DNA methylation-driven gene FAM3D promotes colorectal cancer growth via the ATF4-SESN2-mTORC1 pathway.

Zheng T, Zhang D, Fu Q, Wang M, Cheng Z, Cao Y Aging (Albany NY). 2024; 16(19):12866-12892.

PMID: 39388305 PMC: 11501385. DOI: 10.18632/aging.206115.


References
1.
Yang H, Villani R, Wang H, Simpson M, Roberts M, Tang M . The role of cellular reactive oxygen species in cancer chemotherapy. J Exp Clin Cancer Res. 2018; 37(1):266. PMC: 6211502. DOI: 10.1186/s13046-018-0909-x. View

2.
Ravasco P . Nutrition in Cancer Patients. J Clin Med. 2019; 8(8). PMC: 6723589. DOI: 10.3390/jcm8081211. View

3.
Parmigiani A, Nourbakhsh A, Ding B, Wang W, Kim Y, Akopiants K . Sestrins inhibit mTORC1 kinase activation through the GATOR complex. Cell Rep. 2014; 9(4):1281-91. PMC: 4303546. DOI: 10.1016/j.celrep.2014.10.019. View

4.
Stockwell B, Friedmann Angeli J, Bayir H, Bush A, Conrad M, Dixon S . Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017; 171(2):273-285. PMC: 5685180. DOI: 10.1016/j.cell.2017.09.021. View

5.
Jones C, Stevens B, DAlessandro A, Culp-Hill R, Reisz J, Pei S . Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood. 2019; 134(4):389-394. PMC: 6659257. DOI: 10.1182/blood.2019898114. View